Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

281. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry 28900632 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. 32 10.1038/s41523-017-0033-7 The Recurrence Score (...) ® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence Score-tested through Clalit Health Services from 1/2006 through 12/2011 ( N = 709). Medical records were reviewed to verify treatments/recurrences/survival. Median follow-up, 5.9 years; median age, 62 years; 53.9% grade 2; 69.8% tumors ≤ 2 cm; 84.5% invasive ductal carcinoma; 42.0% N1mi

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

282. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry 28900633 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. 33 10.1038/s41523-017-0034-6 The 21-gene Recurrence Score® (RS) assay is a validated prognostic (...) /predictive tool in ER + early-stage breast cancer. However, clinical outcome data from prospective studies in RS ≥ 11 patients are lacking, as are relevant real-life clinical practice data. In this retrospective analysis of a prospectively designed registry, we evaluated treatments/clinical outcomes in patients undergoing RS-testing through Clalit Health Services. The analysis included N0 ER + HER2-negative breast cancer patients who were RS-tested from 1/2006 through 12/2010. Medical records were

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

283. Leverage of an Existing Cervical Cancer Prevention Service Platform to Initiate Breast Cancer Control Services in Zambia: Experiences and Early Outcomes

Leverage of an Existing Cervical Cancer Prevention Service Platform to Initiate Breast Cancer Control Services in Zambia: Experiences and Early Outcomes 30241176 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Leverage of an Existing Cervical Cancer Prevention Service Platform to Initiate Breast Cancer Control Services in Zambia: Experiences and Early Outcomes. 1-8 10.1200/JGO.17.00026 In 2005, the Cervical Cancer Prevention Program in Zambia (CCPPZ) was implemented (...) and has since provided cervical cancer screen-and-treat services to more than 500,000 women. By leveraging the successes and experiences of the CCPPZ, we intended to build capacity for the early detection and surgical treatment of breast cancer. Our initiative sought to build capacity for breast cancer care through the (1) formation of a breast cancer advocacy alliance to raise awareness, (2) creation of resource-appropriate breast cancer care training curricula for mid- and high-level providers

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

284. Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer

Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer 28884144 2017 09 08 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. 35 10.1038/s41523-017-0030-x [This corrects the article DOI: 10.1038/s41523-017-0015-9.]. Vaysse Charlotte C The Cancer Centre, Oslo University Hospital, Oslo, Norway. 0000 (...) Medicine, University of Oslo, Oslo, Norway. 0000 0004 1936 8921 grid.5510.1 Lofteroed Trygve T The Cancer Centre, Oslo University Hospital, Oslo, Norway. 0000 0004 0389 8485 grid.55325.34 Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 0000 0004 1936 8921 grid.5510.1 Schlichting Ellen E Department of Breast and Endocrine Surgery, Oslo University Hospital, Oslo, Norway. 0000 0004 0389 8485 grid.55325.34 McTiernan Anne A Fred Hutchinson Cancer Research Center, Public Health Sciences

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

286. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial 28661759 2017 06 29 2017 09 08 2017 09 08 1527-7755 35 23 2017 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized (...) Trial. 2639-2646 10.1200/JCO.2017.72.3494 Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2

EvidenceUpdates2017

287. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, contro

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, contro 28600210 2017 06 10 2017 09 11 2017 09 11 1474-5488 18 7 2017 Jul The Lancet. Oncology Lancet Oncol. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy (...) for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. 929-945 S1470-2045(17)30404-7 10.1016/S1470-2045(17)30404-7 Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

288. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy 28682681 2017 07 06 2017 09 15 2017 09 15 1527-7755 35 26 2017 Sep 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. De-Escalation Strategies in Human Epidermal Growth Factor (...) Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. 3046-3054 10.1200/JCO.2016.71.9815 Purpose Human

EvidenceUpdates2017

289. The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasing Anxiety and Depression among Breast Cancer Survivors

The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasing Anxiety and Depression among Breast Cancer Survivors "The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasi" by Haley J. Christensen and Danielle E. Marck > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Breast cancer is one of the most common cancer diagnoses in women, where 1 (...) . The following review aims to determine the continuing efficacy of MBSR on reducing anxiety and depression among breast cancer survivors. Methods: An exhaustive search of available medical literature was performed using MEDLINE- Pubmed, Clinical Key, and Web of Science. Keywords used included: mindfulness, breast cancer, survivors, RCT, and MBSR. Studies were assessed for quality using GRADE criteria. Results: Thirty-seven articles were reviewed. After screening the titles and abstracts for eligibility

Pacific University EBM Capstone Project2017

290. Neratinib maleate (Nerlynx) - To reduce the risk of breast cancer returning

Neratinib maleate (Nerlynx) - To reduce the risk of breast cancer returning Nerlynx (neratinib maleate) Tablets U.S. Department of Health and Human Services Search FDA Submit search Nerlynx (neratinib maleate) Tablets Nerlynx Company: Puma Biotechnology, Inc. Application No.: 208051 Approval Date: 07/17/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 21

FDA - Drug Approval Package2017

291. Ribociclib (Kisqali) - breast cancer

Ribociclib (Kisqali) - breast cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 22 June 2017 EMA/CHMP/506968/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Kisqali International non-proprietary name: ribociclib Procedure No. EMEA/H/C/004213/0000 Note Assessment report as adopted by the CHMP (...) AESI adverse event of special interest AI aromatase inhibitor ALT alanine aminotransferase ANC absolute neutrophil count AST aspartate aminotransferase AUC area under the plasma concentration-time curve BCRP breast cancer resistance protein BCS Biopharmaceutics classification system BIRC Blinded Independent Review Committee BR23 breast cancer specific module of the EORTC QLQ-C30 BSEP bile salt export pump BU Blend uniformity CBR clinical benefit rate CDK cyclin-dependent kinase CFU Colony forming

European Medicines Agency - EPARs2017

292. Effects of FSTL1 on the proliferation and motility of breast cancer cells and vascular endothelial cells

Effects of FSTL1 on the proliferation and motility of breast cancer cells and vascular endothelial cells 28857515 2018 03 20 2018 11 13 1759-7714 8 6 2017 11 Thoracic cancer Thorac Cancer Effects of FSTL1 on the proliferation and motility of breast cancer cells and vascular endothelial cells. 606-612 10.1111/1759-7714.12491 Treatments that prevent the motility of breast cancer cells and inhibit formation of new capillary vessels are urgently needed. FSTL1 is a secreted protein that has been (...) implicated in maintaining the normal physiological function of the cardiovascular system, in addition to a variety of other biological functions. We investigated the role of FSTL1 in the proliferation and migration of breast cancer and vascular endothelial cells. Human umbilical vein endothelial cells and human breast cancer BT-549 cells were used to test the effects of FSTL1 and the N-terminal domain of FSTL1. Immunofluorescence microscopy and 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

293. Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy

Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy August 2017 Technology Description: Breast cancer, a cancer (...) that develops from the tissues of the breast, is the most common cancer in the UK. There are many types of breast cancer and they are often grouped based on the presence or absence of some specific types of proteins (‘receptors’) in the cells of the patient. The most common type of breast cancer are those that are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). The advanced form of the HR+ and HER2- breast cancer occurs when the cancer has spread to other parts

NIHR Innovation Observatory2017

294. Breast Cancer Staging: Is TNM Ready to Evolve?

Breast Cancer Staging: Is TNM Ready to Evolve? 30241210 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Breast Cancer Staging: Is TNM Ready to Evolve? 1-3 10.1200/JGO.17.00004 Cadiz Fernando F Fernando Cadiz, Juan G. Gormaz, and Mauricio Burotto, Clínica Alemana de Santiago; Mauricio Burotto, Universidad del Desarrollo, Santiago, Chile. Gormaz Juan G JG Fernando Cadiz, Juan G. Gormaz, and Mauricio Burotto, Clínica Alemana de Santiago; Mauricio Burotto, Universidad del (...) 20150438 N Engl J Med. 1985 Jun 20;312(25):1604-8 4000199 Lancet. 2017 Jun 17;389(10087):2415-2429 27939064 Ann Oncol. 2011 Aug;22(8):1736-47 21709140 Semin Surg Oncol. 2003;21(1):3-7 12923909 Lancet. 2005 Feb 19-25;365(9460):671-9 15721472 J Natl Compr Canc Netw. 2009 Feb;7(2):122-92 19200416 Breast J. 2013 Jan-Feb;19(1):22-30 23240985 CA Cancer J Clin. 2008 May-Jun;58(3):180-90 18460593 Adv Anat Pathol. 2009 Jul;16(4):204-15 19546609

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

295. Cardiac-sparing radiation therapy using positioning breast shell for patients with left-sided breast cancer who are ineligible for breath-hold techniques

Cardiac-sparing radiation therapy using positioning breast shell for patients with left-sided breast cancer who are ineligible for breath-hold techniques 29204519 2018 11 13 2452-1094 2 4 2017 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Cardiac-sparing radiation therapy using positioning breast shell for patients with left-sided breast cancer who are ineligible for breath-hold techniques. 532-539 10.1016/j.adro.2017.08.002 Patients with left-sided breast cancer (LSBC (...) ) are at increased risk of cardiac morbidity from adjuvant breast radiation therapy (ABRT). Breath-hold (BH) techniques substantially reduce the radiation received by heart during radiation therapy for LSBC. However, a subset of patients with LSBC are ineligible for BH techniques due to an inability to breath-hold or because of other comorbidities. To reduce radiation to the heart, we routinely use a custom-made breast shell for the treatment of patients with LSBC who are ineligible for BH techniques. This study

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

296. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial 28948212 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. 31 10.1038/s41523-017-0025-7 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated (...) in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response and some HR+HER2- patients responded. Pre-specified analysis of five DNA repair deficiency biomarkers (BRCA1/2 germline mutation; PARPi-7, BRCA1 ness, and CIN70 expression signatures; and PARP1 protein) was performed on 116 HER2- patients (VC: 72 and concurrent controls: 44). We also evaluated the 70-gene

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

297. Long non‐coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer

Long non‐coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer 28834648 2018 03 20 2018 11 13 1759-7714 8 6 2017 11 Thoracic cancer Thorac Cancer Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer. 582-591 10.1111/1759-7714.12487 Breast cancer is the most commonly diagnosed cancer in women, and has become the second leading cause of cancer death among women worldwide. Chemoresistance has become an important (...) problem in breast cancer clinics. The identification of new mechanisms affecting chemosensitivity is of great clinical value for the treatment of breast cancer. The expression levels of chemoresistance-associated long non-coding RNA (CRALA), a newly discovered long non-coding RNA, were measured by quantitative real time-PCR in 79 pre-treatment biopsied primary breast cancer samples. Small interfering RNAs were used to knockdown CRALA expression. The effect of CRALA on chemosensitivity was evaluated

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

298. Ribociclib: a valuable addition to treatment options in breast cancer?

Ribociclib: a valuable addition to treatment options in breast cancer? 29302367 2018 11 13 2059-7029 2 3 2017 ESMO open ESMO Open Ribociclib: a valuable addition to treatment options in breast cancer? e000246 10.1136/esmoopen-2017-000246 Bartsch Rupert R Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. eng Editorial 2017 08 23 England ESMO Open 101690685 2059-7029 treatment Competing interests: BS has

ESMO open2017 Full Text: Link to full Text with Trip Pro

299. Patient-reported pain severity, pain interference and health status in HR+/HER2− advanced/metastatic breast cancer

Patient-reported pain severity, pain interference and health status in HR+/HER2− advanced/metastatic breast cancer 29209529 2018 11 13 2059-7029 2 3 2017 ESMO open ESMO Open Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer. e000227 10.1136/esmoopen-2017-000227 Patient-reported pain severity and related impact in advanced/metastatic breast cancer (ABC/MBC) are not well documented. The objective of this study was to assess pain (...) , Manchester, UK. Mitra Debanjali D Global Outcomes and Evidence, Pfizer Inc, New York, USA. de Courcy Jonathan J Real World Evidence, Adelphi Real World, Manchester, UK. Iyer Shrividya S Global Outcomes and Evidence, Pfizer Inc, New York, USA. eng Journal Article 2017 08 22 England ESMO Open 101690685 2059-7029 Advanced Breast Cancer Brief Pain Inventory Eq-5d Metastatic Breast Cancer Real-world Competing interests: None declared. 2017 06 01 2017 07 26 2017 07 26 2017 12 7 6 0 2017 12 7 6 0 2017 12 7 6 1

ESMO open2017 Full Text: Link to full Text with Trip Pro

300. Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes 28856246 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. 30 10.1038/s41523-017-0036-4 Our previous GWAS using samples from the NSABP P-1 and P-2 selective estrogen receptor modulator (SERM) breast cancer prevention trials identified SNPs in ZNF423 (...) and near CTSO that were associated with breast cancer risk during SERM chemoprevention. We have now performed Next Generation DNA sequencing to identify additional SNPs that might contribute to breast cancer risk and to extend our observation that SNPs located hundreds of bp from estrogen response elements (EREs) can alter estrogen receptor alpha (ERα) binding in a SERM-dependent fashion. Our study utilized a nested case-control cohort selected from patients enrolled in the original GWAS, with 199

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro